A new player joins the RNA editing race on the heels of Eli Lilly's $1B-plus deal
A day after Eli Lilly inked a $1 billion-plus deal to partner with a quiet RNA editing startup, a new player has emerged to turn up the volume.
ADARx Pharmaceuticals uncloaked on Thursday with a $75 million Series B round to usher its RNA programs into the clinic. The San Diego-based biotech was founded in 2019 to discover therapies that precisely target and edit single-point mutations on RNA transcripts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.